Annovis Bio (ANVS) Amortizatization of Intangibles (2019 - 2020)
Annovis Bio (ANVS) posted Amortizatization of Intangibles of $396.0 for Q1 2020, down 65.74% sequentially from $1156.0 in Q4 2019, and up 8.49% YoY from $365.0 in Q2 2019.
Annovis Bio (ANVS) Amortizatization of Intangibles (2019 - 2020) Analysis & Trends
Annovis Bio has reported Amortizatization of Intangibles for 2 years, with the latest figure at $396.0 in Q1 2020.
- Quarterly Amortizatization of Intangibles rose 8.49% year-over-year to $396.0 in Q1 2020, while the trailing twelve-month figure through Dec 2020 was $396.0 (down 89.41% YoY) and the FY2020 annual result came in at $396.0, down 89.41% from the prior year.
- Amortizatization of Intangibles declined to $396.0 in Q1 2020 per ANVS's latest filing, from $1156.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1156.0 in Q4 2019 and troughed at $365.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 396.00 |
| Mar 31, 2020 | 396.00 |
| Dec 31, 2019 | 1,156.00 |
| Dec 31, 2019 | 1,156.00 |
| Sep 30, 2019 | 1,128.00 |
| Sep 30, 2019 | 1,128.00 |
| Jun 30, 2019 | 1,089.00 |
| Jun 30, 2019 | 1,089.00 |
| Mar 31, 2019 | 365.00 |
| Mar 31, 2019 | 365.00 |